Hyperbilirubinemia in healthy newborn infants is a common condition treated by pediatric practitioners. Guidelines for the management of hyperbilirubinemia in healthy term newborns were published in 1994 by the American Academy of Pediatrics (1 ) . The guidelines rely heavily on the ability of the physician to recognize jaundice and on the measurement of serum total bilirubin. Thus, the importance of precise and accurate bilirubin results is critical to proper management of hyperbilirubinemia.
Historically, interlaboratory agreement of bilirubin measurements has not been good (2 ) . In 1995, Vreman et al. (3 ) conducted a study on the status of bilirubin measurements in 14 university hospital laboratories in the US. They used commercial lyophilized controls consisting of bovine serum albumin (BSA) 4 enriched with unconjugated bilirubin (UBIL). The instruments used in the study were the Kodak Vitros (then Ektachem; n ϭ 9 sites), Hitachi (n ϭ 3), and Paramax (n ϭ 2). The mean values from the Vitros and the Hitachi instruments were, respectively, 5% and 11% higher than the values assigned by the manufacturer of the lyophilized controls; those from the Paramax were lower by 15%. In the College of American Pathologists (CAP) Survey of the same year, the CV for all Vitros participants was 3.3%, whereas in the study by Vreman et al. (3 ) , the Vitros data had a CV of 17%. The high imprecision reported by Vreman et al. was surprising because according to the authors all nine Vitros instruments used the total bilirubin (TBIL) method (TBIL slide) for measuring bilirubin. Similarly the imprecision (CV ϳ11%) of the three Hitachi analyzers was approxi-mately three times greater than that of all Hitachi participants in the Survey (CV ϳ3.5%). Interestingly, the CVs for all instruments combined in the CAP (CAP-All Instruments) ranged from 7.9% to 8.2%, lower than those for the Vitros and Hitachi reported by Vreman et al. (3 ) .
An editorial that accompanied the report by Vreman et al. (3 ) attributed the excessive variability of the results to lapses in quality assurance procedures, failure to calibrate instruments properly, and possible matrix effects (4 ) .
Examination of the data of the 1995 CAP Survey (Table  1) shows that the mean total bilirubin values obtained with the Hitachi were 15-24 mg/L higher than the AllInstruments mean and that values from the Dimension were 23-34 mg/L higher. Mean values of the Vitros for specimens NB-10 and NB-11 were practically identical to the All-Instruments means, but the mean value for specimen C-96 (125 mg/L), which is the same as NB-11, was ϳ17% lower than the CAP All-Instruments mean (150.2 mg/L). This puzzling discrepancy was not investigated at that time.
To assess the performance of total bilirubin measurements in US laboratories, we analyzed specimens from the CAP Neonatal Bilirubin (NB) and Chemistry (C) Surveys (provided gratis by CAP for this study) by the reference method for total bilirubin (5 ) and compared the results with those reported by laboratories participating in the CAP Surveys. We also found an explanation for the different bilirubin values reported for the same specimen in the NB and C Surveys by the Vitros users.
Materials and Methods
Specimens NB-06, NB-12, NB-13, NB-14, and C-98 were from the 2001 CAP Surveys, whereas C-96, NB-01, and NB-02 were from the 2002 CAP Surveys. Specimen NB-13 is the same as C-98, and specimen NB-02 is the same as C-96. The Survey specimens were shipped to participants in August (NB-06), October (C-98), November (NB-12, NB-13, and NB-14), February (C-96), and April (NB-01 and NB-02). According to information provided by the proficiency material manufacturer, all Survey specimens were bovine serum with added UBIL and ditaurobilirubin (DTB), certain "stabilizers", and antimicrobial agents. The specimens were kept at Ϫ20°C and shipped frozen to participants. The bilirubin concentration in these specimens reportedly remains stable for at least 1 year.
In summarizing the results of the CAP surveys, we grouped similar instruments and methods from the same manufacturer into a single category (see Table 2 ). For example, included under the heading "Roche Hitachi" are Hitachi 911 and 917 and Roche Modular.
Solutions of UBIL and DTB in human serum (obtained after a 12-h fast from two of the authors) were prepared as described by Doumas and coworkers (5, 6 ) . These solutions were dispensed in 1-mL cryogenic vials (Nalgene) and kept at Ϫ70°C; the bilirubin concentrations in these solutions remained unchanged for at least 9 months (UBIL) and 16 months (DTB). These solutions as well as UBIL solutions in BSA were analyzed by the reference method and by the Vitros TBIL and Neonatal Bilirubin (NBIL) methods at Children's Hospital of Wisconsin. The NBIL result is the sum of the unconjugated bilirubin (Bu) and the bilirubin sugar conjugates (Bc), each measured separately by the BuBc slide.
CAP Survey specimens were analyzed in duplicate on 2 days in three laboratories: the Reference Standards Results interlaboratory agreement and differences of results between the reference and participants' methods Table 2 are results from all methods and from four analyzers that provided 75% of the data for the NB Surveys and 83% of the data for the C Surveys. For the NB specimens, three of the four analyzers show very good precision, whereas the Hitachi was somewhat less precise. The interlaboratory CVs for the reference method were quite low, demonstrating the reliability and transferability of the method. Mean bilirubin values from the Hitachi and Synchron analyzers showed small differences from the reference method, whereas the differences for the Dade Dimension and Vitros were, respectively, large and variable. For the most part, the variability among laboratories (All-Instruments CVs) was smaller than in the 1995 Survey.
Summarized in
For three of the four analyzers (Dimension, Hitachi, and Synchron), CVs and differences from the reference method for specimens C-96 and C-98 were, as expected, essentially the same as those for NB-02 and NB-13 because these pairs of specimens differ only in their labeling. However, the means of these specimen pairs were highly divergent when measured by the Vitros users. The Vitros means for the NB specimens were higher than the values by the reference method, whereas for the C specimens, they were lower. These results are similar to those of the 1995 Survey (see Table 1 ). Because of the large difference (9.3 mg/L) between the mean total bilirubin values for C-98 and NB-13, we asked the Data Processing Section of the CAP to recalculate the mean value for C-98 after excluding the values reported by the Vitros users. The recalculated mean for C-98 (188.4 mg/L) was almost identical to that of NB-13 (187.7 mg/L), indicating that the difference in means of C-98 and NB-13 was attributable to the results reported by the Vitros users, who presumably analyzed C-98 by the Vitros TBIL slide and NB-13 by the BuBc slide. Furthermore, after exclusion of the Vitros results, the original CV for C-98 (10.6%) was reduced to 5.6%, which is similar to the CV for NB-13 (4.7%). We also observed a large difference in CV for the identical specimens C-96 (12.1%) and NB-02 (5.4%). A plausible explanation for the large differences in the CV values is that in the NB Surveys, Vitros users reported results obtained by the BuBc slide, whereas in the C Survey both methods (BuBc and TBIL slides) were used by the participants. The Vitros slides were developed to measure Bu and bilirubin glucuronides in human serum, not in bovine serum containing a Bc surrogate, i.e., DTB.
cap nb-survey specimens are inappropriate for evaluating the vitros method for neonatal bilirubin
We investigated the differences in total bilirubin values reported by the Vitros users for the two pairs of identical specimens NB-13/C-98 and NB-02/C-96. We analyzed the Survey specimens on the Vitros 700XR by the TBIL and BuBc slides. The results were similar to those obtained by the Vitros users in the Surveys, i.e., NBIL (Bu ϩ Bc) values obtained by the Vitros BuBc slide exceeded, for every specimen, the values by the TBIL slide. At a low concentration (17 mg/L), the difference [(Bu ϩ Bc) Ϫ TBIL] was small (2 mg/L), whereas at a high bilirubin concentration (146 mg/L), the difference was large (55 mg/L). The Vitros NBIL method (BuBc slide) measures the bilirubin fractions by direct spectrophotometry, whereas total bilirubin is measured by a diazo method. It appears that the CAP Survey specimens exhibit matrix interference in the Vitros TBIL and NBIL methods.
We tried to identify the cause of the difference between the Vitros TBIL and the NBIL values. Knowing that the CAP Survey specimens consist of bovine serum, rather than human serum, enriched with UBIL and DTB, we measured total bilirubin in solutions of UBIL and DTB in fresh human serum by the reference method and by the two Vitros methods. For the high-UBIL solution, the Vitros TBIL and NBIL values were higher than that of the reference method by 4.8% and 8.8%, respectively (Table  3 ). These differences could be attributable to inadequate calibration of the two Vitros methods. Although the reference method values derived from analyses performed over a 9-to 12-month period, both differences were statistically significant because the long-term imprecision of the reference method is low.
For the high-DTB solution, the Vitros TBIL value was 14% lower than that of the reference method, whereas the NBIL value was higher by ϳ19%. Thus, the concentration The effects of protein matrix on the reactivity of DTB and on its absorbance spectrum have been published previously (6 ) . With the reference method, DTB and UBIL have similar reactivities in human serum, human serum albumin, bovine serum, and BSA. Furthermore, the molar absorptivity of the DTB alkaline azopigment at 598 nm is the same as that of UBIL. The underestimation of DTB with the Vitros TBIL slide could be explained if the azopigments deriving from UBIL and DTB have different molar absorptivities. This possibility exists because the diazo reagent of the TBIL slide is different from diazotized sulfanilic acid.
comparison of imprecision in 1995 and 2001
The precision data for the CAP NB Surveys from 1995 and 2001 are summarized and compared in Table 4 . Specimen NB-14 in the CAP 2001 survey is omitted from this summary because of its low total bilirubin concentration (18.4 mg/L). The range of CVs for the four selected instruments is good and clinically acceptable. The precision of these instruments (all show CVs Ͻ5%) has not changed significantly since 1995, suggesting that reagents and calibrators for total bilirubin assays are being manufactured with consistent quality. The improved precision of the CAP All Instruments in 2001 suggests that some of the assays with poorer precision in 1995 had been improved or discontinued in 2001.
Discussion
Because DTB is almost invariably present in commercial controls and calibrators (total bilirubin and direct bilirubin assays are calibrated with a single solution), manufacturers of bilirubin assays based on direct spectrophotometry need to be aware of the dependence of the DTB spectrum on the protein matrix and pH. Given identical DTB concentrations, the spectra of DTB at pH 7.4 (phosphate buffer) in the previously mentioned protein matrices are different (6 ) . In BSA and bovine serum, the spectrum of DTB is biphasic. In human serum albumin and human serum, the DTB spectrum has only one absorbance peak, at 460 nm. In water, the DTB spectrum peak shifts to 450 nm. Changing the pH to 8.5 (Tris buffer) causes the spectra to coalesce into a single spectrum with a peak at ϳ460 nm, but with different molar absorptivities. Furthermore, the molar absorptivities of UBIL are different in human serum and BSA (7, 8 ) . Thus, calibrators consisting of UBIL in BSA (or, presumably, bovine serum) may not have the same values for diazo methods as for direct spectrophotometry. It is possible that the large differences in bilirubin values obtained by the BuBc slide of the Vitros are attributable to the differences in the absorption spectra and molar absorptivity values of DTB and UBIL between bovine serum and human serum.
Achieving accuracy in total bilirubin assays should not be difficult. A Standard Reference Material, SRM 916 Bilirubin, is available from the NIST, and a reference method for total bilirubin (5 ) has been credentialed by the National Reference System for Clinical Laboratories (9 ) . Field methods should be traceable to the reference method and field calibrators to SRM 916. Table 5 measurement) is very small, with CVs for the reference method Ͻ1% (10, 11 ) . In the preparation of bilirubin calibrators, the amount of bilirubin weighed is small, on the order of milligrams. To ascertain that bilirubin calibrators are properly prepared, they should be analyzed by the reference method and the molar absorptivity at 598 nm should be calculated. We recommend acceptability limits of 3 SD above and below the mean value. An additional criterion for acceptability of calibrators is the molar absorptivity of bilirubin in the caffeine reagent. The advantage of this approach, proposed by Vink et al. (12 ) , is that the molar absorptivities of bilirubin at 432 and 457 nm are identical in the three most common protein matrices, i.e., human serum, human serum albumin, and BSA. The primary calibrator for total bilirubin measurement should be SRM 916 (UBIL) in human serum. For methods based on the Jendrassik-Grof principle, calibrators made in human serum, bovine serum, human serum albumin, and BSA are equivalent.
The highest total bilirubin calibrator should be set at 250 mg/L because this is a clinical decision cutoff for the management of hyperbilirubinemia (1 ) . In a healthy, term newborn 48 h or older, a serum total bilirubin Ն250 mg/L will trigger an exchange transfusion if intensive phototherapy fails. A concentration of 250 mg/L is within the linear range of the total bilirubin assays on most major instruments. The Beckman CX and LX Synchron instruments have linear ranges up to 300 mg/L, the Dade Dimension to 250 mg/L, the Roche Hitachi to 300 mg/L, and the Ortho Clinical Diagnostics Vitros to 270 mg/L.
The introduction of proficiency testing specimens based on human serum would provide meaningful information regarding the accuracy and precision of total bilirubin assays. Recently, the CAP has introduced a limited number of human-serum-based specimens in the NB and C Surveys. If this trial is successful and becomes routine, the ability to grade proficiency testing participants for accuracy, using target values determined by the reference method, could become a valuable contribution toward improving the quality of bilirubin assays, which is essential for the management of neonatal hyperbilirubinemia.
